Juan Ignacio Vargas

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study

Josef S Smolen, Aileen L. Pangan, Paul Emery et al. · The Lancet · 2019 · 378 citations

Medicine, Pharmacology, Pharmacotherapy +10

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial

Gerd R Burmester, Yong Lin, Rahul Patel et al. · Annals of the Rheumatic Diseases · 2016 · 316 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension

Mark C. Genovese, Josephine Glover, Maria Greenwald et al. · Arthritis Research & Therapy · 2019 · 50 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study

Kevin Winthrop, Juan Ignacio Vargas, Edit Drescher et al. · RMD Open · 2022 · 13 citations · Full text

Medicine, Clinical Sciences, Immunology +15